National Institute of Allergy and Infectious Diseases (NIAID): all 2,445 studies

Page 10 of 25. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseActive, not recruitingNCT02629120Phase 1/2
• Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in MaliCompletedNCT02627456Phase 1
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy AdultsCompletedNCT02624219Phase 1
• Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in CambodiaCompletedNCT02612545Phase 1
• Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and ChildrenCompletedNCT02601612Phase 1
• Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT02599896Phase 1
• Influenza A H3N2 Human Challenge Study in Healthy Adult VolunteersCompletedNCT02594189Phase 1
• H7N9 Boost in Healthy AdultsCompletedNCT02586792Phase 2
• Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy AdultsCompletedNCT02564575Phase 1
• Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian AdultsCompletedNCT02544048
• Sputum Pharmacokinetics of TB Drugs and Bacterial Drug ResistanceCompletedNCT02534727
• Phase 1 Study of dmLT ID Vaccination in Healthy AdultsCompletedNCT02531685Phase 1
• Registry for Asthma Characterization and Recruitment 2CompletedNCT02513264
• Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...CompletedNCT02511054Phase 1
• Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of GlycosylationTerminatedNCT02511041Phase 1
• Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult SubjectsCompletedNCT02508376Phase 1
• Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian ChildrenCompletedNCT02504918
• Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based TherapyCompletedNCT02502890
• Respiratory Syncytial Virus Human Challenge in Healthy Adult VolunteersCompletedNCT02484417Phase 1
• Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge StudiesCompletedNCT02473224Phase 1
• Safety and PK of MBX-400 (Cyclopropavir) in Normal VolunteersCompletedNCT02454699Phase 1
• Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)CompletedNCT02450838Phase 1
• Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2CompletedNCT02433652Phase 1
• Ebola Virus Disease Survivors: Clinical and Immunologic Follow-upCompletedNCT02431923
• Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected AdultsCompletedNCT02431767Phase 1
• Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048CompletedNCT02419456Phase 1
• NIAID Clinical Center Genomics Opportunity ProtocolCompletedNCT02417766
• VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy AdultsCompletedNCT02408913Phase 1
• Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy AdultsCompletedNCT02392325Phase 1
• Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult VolunteersWithdrawnNCT02389192Phase 1
• NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in TuberculosisCompletedNCT02371681Phase 2
• Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048CompletedNCT02356302Phase 1
• Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in UgandaCompletedNCT02354404Phase 1
• Genitourinary and Pharyngeal Pharmacokinetics of SolithromycinCompletedNCT02348424Phase 1
• Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious DiseasesCompletedNCT02338986
• Phase 1 Trial of Inactivated West Nile Virus VaccineCompletedNCT02337868Phase 1
• A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy AdultsCompletedNCT02337855Phase 1
• Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)WithdrawnNCT02337842Phase 1
• Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and MaliCompletedNCT02334462Phase 1
• Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in ThailandCompletedNCT02332733Phase 2
• Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple SclerosisCompletedNCT02330965
• Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy AdultsCompletedNCT02317900Phase 1
• A Randomized Prospective Clinical Trial of Fel d 1 Peptide ImmunotherapyCompletedNCT02311413Phase 2
• Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, MaliCompletedNCT02311387
• Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected AdultsCompletedNCT02296541Phase 1
• Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years OldCompletedNCT02274545Phase 1
• Human Immunity Against Staphylococcus Aureus Skin InfectionCompletedNCT02262819Phase 1
• Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 StudyCompletedNCT02255123
• A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus VaccineCompletedNCT02251288Phase 1
• Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral ProductsCompletedNCT02242968
• Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT02237209Phase 1
• People Presenting With Neurocysticercosis in North AmericaTerminatedNCT02233855
• Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous DiseaseCompletedNCT02233036
• Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy AdultsCompletedNCT02231866Phase 1
• Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth InfectionTerminatedNCT02225158
• H7N9 Mix and Match With MF59 in Healthy Elderly PersonsCompletedNCT02213354Phase 2
• Impact of Vaccination on Th2 Immunity in InfancyTerminatedNCT02213341
• Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected AdultsCompletedNCT02207920Phase 1
• H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...CompletedNCT02206464Phase 1
• Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in MaliCompletedNCT02206451
• Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of AgeCompletedNCT02186626Phase 1
• Biomarkers for Post-Transplant Lymphoproliferative Disorders in ChildrenCompletedNCT02182986
• Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy SubjectsCompletedNCT02178254Phase 1
• Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected AdultsCompletedNCT02165267Phase 1
• Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC)CompletedNCT02163122Early Phase 1
• Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United StatesTerminatedNCT02153996
• Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying IntervalsCompletedNCT02151344Phase 1
• Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural FairsCompletedNCT02124096
• Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995CompletedNCT02116764
• ADRN Barrier/Immunoprofiling Exploratory Pilot StudyCompletedNCT02115399
• Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.CompletedNCT02106338Phase 1
• Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic SyndromeStatus unknownNCT02101138Phase 2
• Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric PopulationsCompletedNCT02100436Phase 2
• Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in UgandaCompletedNCT02094508
• Auranofin PK Following Oral Dose AdministrationCompletedNCT02089048Phase 1
• Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995Status unknownNCT02082353
• Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-PlerixaforTerminatedNCT02069080Early Phase 1
• Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990CompletedNCT02064933
• Safety of Sublingual dmLT for ETECCompletedNCT02052934Phase 1
• Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT02040831Phase 1
• A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy SubjectsWithdrawnNCT02037282Phase 1
• Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral TherapyCompletedNCT02028403Phase 1
• Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy AdultsCompletedNCT02021968Phase 1
• Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive AdultsCompletedNCT02015091Phase 1
• Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)CompletedNCT02008578Phase 1
• Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy AdultsCompletedNCT01995695Phase 1
• Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT01993706Phase 1
• Study of Safety and Immunogenicity of HIV Vaccines in Healthy VolunteersCompletedNCT01989533Phase 1
• Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African AdultsCompletedNCT01988636Phase 1
• Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral TherapyCompletedNCT01976715
• Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of AgeWithdrawnNCT01975012Phase 1/2
• A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 StudyCompletedNCT01974999
• Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected AdultsWithdrawnNCT01970449Phase 1
• Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and ChildrenCompletedNCT01968083Phase 1
• Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected AdultsWithdrawnNCT01964937Phase 1
• VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...CompletedNCT01950325Phase 1
• The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot StudyCompletedNCT01949363Phase 1
• T and B Cell Responses in Autoimmune DiseasesTerminatedNCT01947036
• H7N9 Mix and Match With AS03 and MF59 in Healthy AdultsCompletedNCT01942265Phase 2
• H7N9 Mix and Match With MF59 in Healthy AdultsCompletedNCT01938742Phase 2

← National Institute of Allergy and Infectious Diseases (NIAID) overview and focus areas